VitalHub Reports Q3 2022 Financial Results with Record Revenue of $9.8M and Adjusted EBITDA of $2.2M
November 10 2022 - 7:41PM
VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI)
(OTCQX:VHIBF) announced today it has filed its Interim Condensed
Consolidated Financial Statements and Management's Discussion and
Analysis report for the three and nine months ended September 30,
2022, with the Canadian securities authorities. These documents may
be viewed under the Company's profile at www.sedar.com.
VitalHub’s Chief Executive Officer Dan Matlow
commented,
“Despite Q3 historically having been our
seasonally weakest quarter, and notwithstanding the foreign
currency headwinds associated with the British pound, Q3 2022 saw
continued and consistent improvement across all of our key
indicators, quarter over quarter. We continued to grow our organic
annual recurring revenue by adding another $850K on a constant
currency basis, and achieved another record adjusted EBITDA of $2.2
million for the quarter. With the addition of the Community Data
Solutions and Advanced Digital Innovation acquisitions, our ARR
stands at close to $34 million. We have significant cash on hand
and the availability of a Bank of Nova Scotia Facility, together
totaling $48 million available to continue our strategic
acquisition strategy, while we continue to generate significant
cash from operations that we expect to continue to grow. We have
never been in a better position than we are in at the present
time.”
VitalHub’s quarterly investor conference call
will take place on Friday, November 11, 2022, at 9:00AM EST. To
join the call, please
dial 1-888-664-6383 (Toll-Free North
America) or 416-764-8650 (Local –
Toronto) and enter confirmation number
13111266.
A replay of the call will be available until
Friday, December 11, 2022, and can be accessed by
dialing 1-888-390-0541 (Toll-Free North
America) or 416-764-8677 (Local –
Toronto), using the replay entry
code 111266#.
Third Quarter 2022
Highlights
- Revenue of $9,780,553, an increase
of $3,161,506 or 48% from the comparative period in the prior
year.
- Gross profit as a percentage of
revenue for Q3 2022 was 80% compared to 82% in Q3 2021.
- ARR (1, 2) at the end of Q3 2022
was $30,967,215.
- Organic growth of $850,755 or 2.73%
from Q2 2022,
- Reduction of $1,103,048 or 3.53%
due to the decrease in the value of the GBP pound relative to the
CAD dollar from the prior quarter.
- EBITDA (2) of $1,389,065 compared
to $189,088 in the comparative period in the prior year.
- Adjusted EBITDA (2) of $2,151,753,
or 22% of revenue, compared to $1,277,573 or 19% of revenue in the
comparative period in the prior year.
- Cash on hand at September 30, 2022
was $36,065,885 compared to $16,389,982 as at December 31,
2021.
- During the quarter, the Company
secured additional financing from The Bank of Nova Scotia.
Increasing its operating credit limit from $1,000,000 to $6,000,000
and its revolving term facility from $10,000,000 to
$27,000,000.
- Subsequent to the quarter, the
Company acquired all of the issued and outstanding shares of QWAD
Community Technologies Pty Ltd, doing business as “Community Data
Solutions” (“CDS”), a company incorporated and conducting business
in Australia. CDS offers an online case management system and
supporting products serving 350+ agencies located in all states and
internal territories of Australia. Total closing consideration for
the acquisition was all-cash for a purchase price at closing of
approximately AUD $8,197,155 (CAD $7,110,663), which was after
customary closing and working capital adjustments.
- Subsequent to the quarter, the
Company acquired certain assets to maintain the business of
Advanced Digital Innovation (UK) Limited (“ADI”) with the product
widely known as MyPathway. MyPathway is a digital health platform
which is used to improve patient interactions during treatment.
Total closing consideration for the acquisition was all-cash for a
purchase price of approximately GBP 250,000 (CAD $382,740).
- Subsequent to the quarter, the
Company repaid the balance of its Scotia revolving facility loan in
the amount of $8,999,982.
- With the addition of the ARR(1, 2)
of CDS and ADI subsequent to the quarter, the Company’s proforma
ARR would be approximately $34,000,000.
Nine Month 2022 Highlights
- Revenue of $28,681,209, an increase
of $10,946,909 or 62% from the comparative period in the prior
year.
- Gross profit as a percentage of
revenue for the nine months ended was 82% compared to 79% from the
comparative period in the prior year.
- ARR (1, 2) at September 30, 2022
was $30,967,215 as compared to $21,569,032 at September 30, 2021,
an increase of 44%.
- EBITDA (2) of $ 4,779,798 compared
to $645,439 in the comparative period in the prior year.
- Adjusted EBITDA (2) of $ 7,069,334
as, or 25% of revenue, compared to $ 3,197,090 or 18% of revenue in
the comparative period in the prior year.
- Cashflow from operations before
changes in working capital was $5,280,072 for the period as
compared to $1,394,927 for the same period last year.
(1) The Company defines annual recurring revenue
(“ARR”) as the recurring revenue expected based on yearly
subscriptions of the renewable software license fees and
maintenance services.(2) Non-IFRS measure.
Q3 2022 and 2021 Results
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
Nine months ended |
|
2022 |
%Revenue |
2021 |
%Revenue |
Change |
2022 |
%Revenue |
2021 |
%Revenue |
Change |
|
$ |
|
$ |
|
% |
$ |
|
$ |
|
% |
Revenue |
9,780,553 |
|
100% |
6,619,047 |
|
100% |
48% |
28,681,209 |
100% |
17,734,300 |
|
100% |
62% |
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
1,952,398 |
|
20% |
1,174,244 |
|
18% |
66% |
5,032,259 |
18% |
3,773,770 |
|
21% |
33% |
|
|
|
|
|
|
|
|
|
|
|
Gross Profit |
7,828,155 |
|
80% |
5,444,803 |
|
82% |
44% |
23,648,950 |
82% |
13,960,530 |
|
79% |
69% |
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses |
|
|
|
|
|
|
|
|
|
|
General and administrative |
2,086,415 |
|
21% |
1,361,762 |
|
21% |
53% |
6,007,993 |
21% |
3,638,214 |
|
21% |
65% |
Sales and marketing |
1,076,673 |
|
11% |
974,506 |
|
15% |
10% |
3,148,312 |
11% |
2,646,543 |
|
15% |
19% |
Research and development |
2,622,921 |
|
27% |
1,875,775 |
|
28% |
40% |
7,365,681 |
26% |
4,328,219 |
|
24% |
70% |
Depreciation |
69,992 |
|
1% |
42,625 |
|
1% |
64% |
173,865 |
1% |
117,314 |
|
1% |
48% |
Depreciation of right-of-use assets |
64,158 |
|
1% |
71,006 |
|
1% |
(10%) |
179,640 |
1% |
201,769 |
|
1% |
(11%) |
Stock based compensation |
289,019 |
|
3% |
484,226 |
|
7% |
(40%) |
872,803 |
3% |
1,088,306 |
|
6% |
(20%) |
Foreign currency (gain) loss |
(109,607 |
) |
(1%) |
(44,469 |
) |
(1%) |
146% |
56,573 |
0% |
148,311 |
|
1% |
(62%) |
|
|
|
|
|
|
|
|
|
|
|
Other Income and Expenses |
|
|
|
|
|
|
|
|
|
|
Amortization of intangible assets |
847,818 |
|
9% |
637,685 |
|
10% |
33% |
2,327,016 |
8% |
1,618,502 |
|
9% |
44% |
Business acquisition, restructuring and integration costs |
473,669 |
|
5% |
604,259 |
|
9% |
(22%) |
1,416,733 |
5% |
1,463,345 |
|
8% |
(3%) |
Interest expense and accretion (net of interest income) |
(75,059 |
) |
(1%) |
(7,292 |
) |
(0%) |
929% |
30,626 |
0% |
(25,584 |
) |
(0%) |
(220%) |
Interest income from sublease |
0 |
|
0% |
0 |
|
0% |
0% |
0 |
0% |
0 |
|
0% |
0% |
Interest expense from lease liabilities |
72,658 |
|
1% |
20,856 |
|
0% |
248% |
105,594 |
0% |
64,236 |
|
0% |
64% |
(Gain) loss on disposal of property and equipment |
0 |
|
0% |
(344 |
) |
(0%) |
100% |
1,057 |
0% |
2,153 |
|
0% |
(51%) |
|
|
|
|
|
|
|
|
|
|
|
Current and deferred income taxes |
368,721 |
|
4% |
0 |
|
0% |
(100%) |
410,087 |
1% |
10,071 |
|
0% |
3972% |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
40,777 |
|
0% |
(575,792 |
) |
(9%) |
107% |
1,552,970 |
5% |
(1,340,869 |
) |
(8%) |
(216%) |
|
|
|
|
|
|
|
|
|
|
|
EBITDA(Non-IFRS measure) |
1,389,065 |
|
14% |
189,088 |
|
3% |
635% |
4,779,798 |
17% |
645,439 |
|
4% |
641% |
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA(Non-IFRS
measure) |
2,151,753 |
|
22% |
1,277,573 |
|
19% |
68% |
7,069,334 |
25% |
3,197,090 |
|
18% |
121% |
|
|
|
|
|
|
|
|
|
|
|
Annual Recurring Revenue(Non-IFRS
measure) |
30,967,215 |
|
|
21,569,032 |
|
|
44% |
30,967,215 |
|
21,569,032 |
|
|
44% |
|
|
|
|
|
|
|
|
|
|
|
Recurring revenue(Non-IFRS
Measure) |
7,657,559 |
|
78% |
5,462,774 |
|
83% |
40% |
20,623,096 |
72% |
13,960,056 |
|
79% |
48% |
|
|
|
|
|
|
|
|
|
|
|
Deferred revenue |
15,232,153 |
|
|
8,821,331 |
|
|
|
15,232,153 |
|
8,821,331 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash balance |
36,065,885 |
|
|
16,389,982 |
|
|
|
36,065,885 |
|
16,389,982 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ABOUT VITALHUB
Software for Health and Human Services providers
designed to simplify the user experience & optimize
outcomes.
Vitalhub provides technology to Health and Human
Services providers including; Hospitals, Regional Health
Authorities, Mental Health, Long Term Care, Home Health, Community
and Social Services. Vitalhub solutions span the categories of
Electronic Health Record (EHR), Case Management, Care Coordination,
Patient Flow & Operational Visibility, and DOCit Mobile Apps.
The Company has a robust two-pronged growth strategy, targeting
organic growth opportunities within its product suite, and pursuing
an aggressive M&A plan. Currently, Vitalhub serves 275+ clients
across Canada, USA, UK, Australia, Qatar, and Latvia. Vitalhub is
based in Toronto, Canada, with an offshore development hub in Sri
Lanka. The Company is publicly traded on the TSX Venture Exchange
under the symbol “VHI”.
CAUTIONARY STATEMENT
This press release includes forward-looking
statements regarding the Corporation and its business, which may
include, but is not limited to, statements with respect to the
appointment of a new directors. Often, but not always,
forward-looking statements can be identified by the use of words
such as "plans", "is expected", "expects", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes" or variations
(including negative variations) of such words and phrases, or state
that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such statements
are based on the current expectations of the management of each
entity and are based on assumptions and subject to risks and
uncertainties. Although the management of each entity believes that
the assumptions underlying these statements are reasonable, they
may prove to be incorrect. The forward-looking events and
circumstances discussed in this release, may not occur by certain
specified dates or at all and could differ materially as a result
of known and unknown risk factors and uncertainties affecting the
companies, including risks regarding the technology industry,
failure to obtain regulatory or shareholder approvals, market
conditions, economic factors, the equity markets generally and
risks associated with growth and competition. Although the
Corporation has attempted to identify important factors that could
cause actual actions, events or results to differ materially from
those described in forward-looking statements, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement
can be guaranteed. Except as required by applicable securities
laws, forward-looking statements speak only as of the date on which
they are made and the Corporation undertakes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events, or otherwise.
CONTACT INFORMATION
Dan MatlowChief Executive Officer, Director(416)
727-9061dan.matlow@Vitalhub.com
Vitalhub (TSX:VHI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Vitalhub (TSX:VHI)
Historical Stock Chart
From Dec 2023 to Dec 2024